In vitro studies revealed that TM6SF2 siRNA inhibition was associated with the reduced secretion of very-low density lipoproteins (VLDLs) and increased cellular TG concentrations and lipid droplet levels, whereas TM6SF2 overexpression reduced liver cell steatosis [76]. This evidence concerns the gene TM6SF2 and steatosis.